Madrigal Pharmaceuticals Inc [NASDAQ: MDGL] stock went on an upward path that rose over 1.52% on Wednesday, amounting to a one-week price increase of more than 8.18%.
Over the last 12 months, MDGL stock rose by 94.78%. The one-year Madrigal Pharmaceuticals Inc stock forecast points to a potential downside of -6.97. The average equity rating for MDGL stock is currently 1.12, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $13.65 billion, with 22.70 million shares outstanding and 20.63 million shares in the current float. Compared to the average trading volume of 356.90K shares, MDGL stock reached a trading volume of 254356 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on Madrigal Pharmaceuticals Inc [MDGL]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for MDGL shares is $561.88 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on MDGL stock is a recommendation set at 1.12. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cantor Fitzgerald have made an estimate for Madrigal Pharmaceuticals Inc shares, keeping their opinion on the stock as Overweight, with their previous recommendation back on November 05, 2025. The new note on the price target was released on November 03, 2025, representing the official price target for Madrigal Pharmaceuticals Inc stock. Previously, the target price had yet another raise to $580, while Truist analysts kept a Buy rating on MDGL stock.
The Price to Book ratio for the last quarter was 21.81, with the Price to Cash per share for the same quarter was set at 49.08.
MDGL Stock Performance Analysis:
Madrigal Pharmaceuticals Inc [MDGL] gain into the green zone at the end of the last week, gaining into a positive trend and gaining by 8.18. With this latest performance, MDGL shares gained by 40.04% in over the last four-week period, additionally plugging by 122.66% over the last 6 months – not to mention a rise of 94.78% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for MDGL stock in for the last two-week period is set at 76.64, with the RSI for the last a single of trading hit 28.80, and the three-weeks RSI is set at 25.45 for Madrigal Pharmaceuticals Inc [MDGL]. The present Moving Average for the last 50 days of trading for this stock 467.18, while it was recorded at 574.21 for the last single week of trading, and 364.28 for the last 200 days.
Insight into Madrigal Pharmaceuticals Inc Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and Madrigal Pharmaceuticals Inc [MDGL] shares currently have an operating margin of -41.52% and a Gross Margin at 95.06%. Madrigal Pharmaceuticals Inc’s Net Margin is presently recorded at -39.04%.
Madrigal Pharmaceuticals Inc (MDGL) Capital Structure & Debt Analysis
According to recent financial data for Madrigal Pharmaceuticals Inc. ( MDGL), the Return on Equity (ROE) stands at -41.22%, highlighting a negative impact on investor capital. The Return on Assets (ROA) is -23.74%, reflecting the company’s efficiency in generating profits from its assets. Additionally, Madrigal Pharmaceuticals Inc’s Return on Invested Capital (ROIC) is -29.77%, showcasing its effectiveness in deploying capital for earnings.
Madrigal Pharmaceuticals Inc (MDGL) Efficiency & Liquidity Metrics
Based on Madrigal Pharmaceuticals Inc’s (MDGL) latest financial statements, the Debt-to-Equity Ratio is 0.55%, indicating its reliance on debt financing relative to shareholder equity.
Madrigal Pharmaceuticals Inc (MDGL) Efficiency & Liquidity Metrics
From an operational efficiency perspective, Madrigal Pharmaceuticals Inc. (MDGL) effectively leverages its workforce, generating an average of -$547575.76 per employee. The company’s liquidity position is robust, with a Current Ratio of 3.44% and a Quick Ratio of 3.26%, indicating strong ability to cover short-term liabilities.
MDGL Stock EPS
With the latest financial reports released by the company, Madrigal Pharmaceuticals Inc posted -2.71/share EPS, while the average EPS was predicted by analysts to be reported at -4.12/share. When compared, the two values demonstrate that the company surpassed the estimates by a Surprise Factor of 1.41. The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for MDGL.
Madrigal Pharmaceuticals Inc [MDGL] Institutonal Ownership Details
There are presently around $105.04%, or 113.60%% of MDGL stock, in the hands of institutional investors. The top three institutional holders of MDGL stocks are: JANUS HENDERSON GROUP PLC with ownership of 2.49 million shares, which is approximately 11.6142%. AVORO CAPITAL ADVISORS LLC, holding 2.06 million shares of the stock with an approximate value of $$575.88 million in MDGL stocks shares; and AVORO CAPITAL ADVISORS LLC, currently with $$553.2 million in MDGL stock with ownership which is approximately 9.2259%.
